Aphex BioCleanse Systems, Inc. announced that the Company has entered into an agreement with Now Biopharma to conduct a hand sanitizer clinical trial in accordance with Federal Register Document No. RIN0910, Safety and Efficacy of Health Care Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use. Final Rule (Dec. 20, 2017). The clinical protocol for this study will include 300 human subjects and compare the Aphex hand sanitizer HydrAphex® to an approved alcohol based product and a saline control. HydrAphex® is a hand sanitizer that can be used without water and includes Hy-IQ™ Water. When used as directed, Hy-IQ™ quickly drips off, evaporates, or otherwise leaves no significant chemical residue. The product has been shown to inactivate vegetative bacteria and fungi, bacterial spores, and viruses. It has also been shown in testing to be effective against the 229E Strain (SARS-CoV-2) of the human coronavirus. The safety of this product is based upon the fact that the finished product is water with an increased concentration of hydrogen ions and trace levels of residual sulfates. In addition to the active ingredient Hy-IQ™ Water being used in this clinical trial, it has also been reviewed and submitted to the FDA as a GRAS (Generally Regarded as Safe) active ingredient for use with food products. The Company is currently seeking FDA final review and approval.